bacterico is a biotechnology startup developing personalized healthcare solutions based on an individual’s own gut microbiome. We isolate, select, and cultivate Bifidobacterium strains from stool samples and enhance them using proprietary culture methods to create personalized probiotic supplements optimized for each person’s gut environment. We also provide evidence-based programs tailored to key life moments, including Mama Flora, which supports maternal and infant health through prenatal gut microbiome care, and Preflora, a personalized nutrition and gut-health program designed specifically for individuals who are actively trying to conceive. Through science-driven, individualized interventions, bacterico aims to bring safe and effective microbiome-based solutions to everyday health.
[画像1: https://prtimes.jp/i/111676/2/resize/d111676-2-06f70f0da77fcc8956b1-0.png ] 株式会社bacterico（バクテリコ）は、一人ひとりの腸内フローラのデータに基づいて、自分に合った栄養指導などが専門家か...
[画像1: https://prtimes.jp/i/111676/1/resize/d111676-1-60da72fa9b6a1052da72-0.png ] 「mamaflora」とは、赤ちゃんが生まれる前から健やかな成長を支援することを目指し、一人ひとり異なる腸内細菌データに...
Cells in living organisms function in an orderly manner by cooperating with surrounding cells while interacting with extracellular proteins. However, in cell culture systems, extracellular proteins are largely absent, making it difficult for cells to function properly and often causing them to exhibit physiological activities that differ from those observed in vivo. Our company conducts research on extracellular matrix proteins located outside the cell, and by applying the findings from this research to cell culture technologies, we aim to contribute to the advancement of regenerative medicine and the realization of alternatives to animal experimentation.
A startup advancing drug discovery through proprietary platform technology that selectively delivers drugs to immune cells, both through in-house development and collaborative partnerships. It aims to create novel therapies for intractable diseases by controlling immune responses.
Neocure prevents 30,000 children from going blind each year due to ROP using AI technology. ROP can be treated, but it is often hard to find in time. Our AI analyzes the risk for each baby, helping to prevent missed diagnoses in hospitals where there aren't enough eye specialists. By helping doctors focus on the most urgent cases, we can stop blindness caused by ROP.
L-glucose, a mirror isomer of D-glucose, is usually considered unusable by living organisms. However, in 2010, we discovered that malignant tumor cells specifically take up L-glucose (patented internationally). We have since worked with physicians and researchers to develop cancer-targeting drugs and diagnostics using L-glucose. Our goal is to bring a cure to patients with intractable cancers.
